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Abstract
Objectives: In this paper, we describe the steps followed
for the development of a certified reference material for
immunoglobulin G antibodies against β2-glycoprotein I
(also known as apolipoprotein H). These steps include
processing of the material, commutability, the impact of
dilution, the appropriate reconstitution conditions, ho-
mogeneity and stability during transport and storage.
Methods: We analysed 69 clinical samples from patients
suffering from antiphospholipid syndrome with several
commercial enzyme-linked immunosorbent assays (ELISA)
purchased from in vitro diagnostic manufacturers.
Results: Analysis of the results indicated that the candi-
date reference material can be safely freeze-dried, and that
the user should carefully follow the reconstitution in-
structions as small changes in e.g. temperature may have
unwanted effects. The statistical analysis of the commut-
ability studies indicated that the analytical response of the
referencematerial upondilution is similar to that of clinical
samples, and that correlation between results may differ
from assay to assay. Finally yet importantly, the presented
and developed candidate reference material is commut-
able for most assays tested, homogeneous and stable.
Conclusions: Immunoglobulin G antibodies against β2-
glycoprotein I are associated with a higher risk of throm-
bosis and pregnancy complications. Their measurement is
essential for the diagnosis and monitoring of anti-
phospholipid syndrome. These antibodies are detected by
specific immunoassays, routinely used in clinical di-
agnostics, but various of these methods show enormous
variability, in part due to the lack of a reference material.
Keywords: autoimmune testing; certified reference mate-
rials; harmonization; proteinase 3; standardization.
Introduction
Anti-β2GPI and disease
Antibodies against-β2-glycoprotein I (anti-β2GPI) are rec-
ognised as one of the criteria for the diagnosis for anti-
phospholipid syndrome (APS). APS is a disorder causing
vascular thrombosis and/or obstetric complications [1]. It
has a wide range of potential manifestations, with some of
them, typically being recurrent early miscarriages, pre-
eclampsia and late foetal loss [2]. Diagnosis relies on
clinical manifestations in combination with the measure-
ment of antiphospholipid antibodies. Antiphospholipid
antibodies are a general name given to several different
analytes but only three are agreed in the current
consensus guidelines to be important in diagnosis of APS
[3]. These are the lupus anticoagulant (LA), anti-
cardiolipin antibodies (aCL) and the anti-β2GPI, which is
a predominant target in the pathogenesis of APS. In
addition to the above, test results indicating the presence
of anti-β2GPI antibodies should be detected for a period no
smaller than 12 weeks or no more than five years should
pass between two positive tests [3]. When B2GPI is used, in
an assay preparation and development, in combination
with CL, serves as a target antigen for aCL assays, while in
the case where only B2GPI is used, it serves as a target
antigen for anti-β2GPI assays [4]. Additionally, anti-β2GPI
antibodies are responsible for the response in most of the
*Corresponding author: Evanthia Monogioudi, European
Commission – Joint Research Centre (JRC), Geel, Belgium, Phone: +32
14 571906, E-mail: Evanthia.monogioudi@ec.europa.eu.
https://orcid.org/0000-0001-8525-8921
Gustavo Martos, European Commission – Joint Research Centre (JRC),
Geel, Belgium; International BureauofWeights andMeasures, Sèvres,
France
Joanna Sheldon, St. George’s Hospital, Protein Reference Unit,
London, UK
Pier Luigi Meroni, University of Milan, IRCCS Instituto Auxologico
Italiano, Milan, Italy
Stefanie Trapmann and Ingrid Zegers, European Commission – Joint
Research Centre (JRC), Geel, Belgium
Clin Chem Lab Med 2021; 59(2): 325–332
Open Access. © 2020 Evanthia Monogioudi et al., published by De Gruyter. This work is licensed under the Creative Commons Attribution 4.0
International License.
LA assays and β2GPI-dependent LA are the ones predictive
for thrombosis and foetal loss [5].
Anti-β2GPI measurements
Measurement of anti-β2GPI IgG antibodies is possible via a
number of commercial or in house prepared enzyme-linked
immunosorbent assays (ELISAs). Each assay uses its own
buffers, sample dilution schemes, antigens, calibrants and
arbitrary units. Despite the fact that each assay may work
perfectly well in itself, this diversity renders difficult to
compare results for the same patient but analysed with
different kits. In the absence of an internationally accepted
standard, it is impossible to have accurate, quantitative
results that are comparable between method and in an
individual patient over time.
Comparability of results from different
assays
It is widely known that results between assays vary due to a
number of factors independently of their individual per-
formance. These factors have been summarised elsewhere
[6]. With the exception of the sample specific variation and
inevitably the different scales employed in the immuno-
assays used, all other factors are considered in our studies.
In this paper, we present the results of the correlation
studies for anti-β2GPI IgG assays, report the results in
analytical terms, and describe the effect of freeze-drying
processing on the material, the behaviour of a candidate
referencematerial when diluted and the best conditions for
reconstituting the candidate referencematerial to retain its
characteristics. Additionally we report the between- and
within- vial homogeneity of the produced material, its
short and long-term stability.
Anti-β2GPI CRM and need
The Committee on Harmonization of Autoimmune Testing
(C-HAT) of the International Federation of Clinical Chem-
istry and Laboratory Medicine (IFCC) in collaboration with
the Joint Research Institute of the European Commission
(EC-JRC) has studied the possibility of developing a certi-
fied reference material (CRM) with an assigned property
value (anti-β2GPI IgG antibodies concentration in a matrix
material). It could serve as a quality control of anti-β2GPI
IgG measurements or for the calibration of immunoassay-
based in vitro diagnostic devices.
For a material to be selected as a candidate CRM, it has
to be commutable. In simple terms, it needs to resemble a
random and typical clinical sample [7]. If such a material is
found and used as a candidate CRM, then calibration bias
canbeminimisedand thematerial canbeof value [8–11].We
have monitored the commutability of several candidate
materials since the beginning of this project. We have ana-
lysed the candidate CRM samples freeze-dried or in liquid
form together with a representative number of clinical
samples across various assays. At the end of our studies and
trials, we did find a material that was commutable with a
representative number of commercial immunoassays.
Materials and methods
Serum samples
Clinical samples were collected based on the amounts available and
their β2GPI IgG concentration. Separate commutability assessments
were performedand in total 69 serum samples (30 in the first studyand
39 in the second) were used. Serum samples were from patients un-
dergoing β2GPI IgG testing and were provided by the University of
Texas Medical Branch (Texas, USA) for the first study and from the
Protein Reference Unit and Immunopathology Department, St.
Georges’ Hospital (London, UK) and from Instituto Auxocologico
Italiano (Milan, IT) for the second. Each sample was anonymised
following national ethical laws.
Candidate reference materials processing
Starting plasmapheresis material (approximately 4 L), collected from
two patients diagnosed with APS was provided by Silvia Pierangeli
from the University of Texas Medical Branch (Texas, USA). It was
converted into serum by precipitation of clotting factors with prot-
amine sulphate, delipidated and enhanced with preservatives (so-
dium azide, aprotinin and benzamidine hydrochloride). The material
was filtered through 0.22 µm filter prior to filling into vials and freeze-
dried. Filling precision is a critical parameter due to the following
freeze-drying. Therefore, 23 vials were weighed throughout the filling
process and the first 2,860 filled vials were taken to the subsequent
lyophilisation step. Another 454 vials were kept aside and kept in
liquid frozen form at −70 °C due to the slight increase in the filling
volume. The relative standard deviation of the masses of the filling
solution of the main batch was 0.15%, well below the target level
(<1%).Water contentwas estimated to be 0.81± 0.02%,which is safely
below the target level (<2%).
Commutability and dilution studies
Two commutability studies were performed. The first one included
four commercial immunoassays, 30 clinical samples and four di-
lutions of freeze-dried and liquid frozen candidate material. The
purpose of that study was primarily to monitor the effect of freeze-
drying on the material. The second one included seven
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immunoassays, the chosen material (analysed at eight dilutions) and
39 clinical samples (CS). For the commutability studies, all ELISA
measurements were performed on two plates per assay. Dilutions of
the freeze-dried candidate RM and the CSs were analysed at least in
duplicate on each of two ELISA plates per assay. Various dilutions
were included in the analysis to ensure that the RM concentrations
were within themeasurement interval of the assays. All reconstitution
and dilution volumes were gravimetrically controlled and the dilution
levels were calculated from the masses and the densities rather than
from the intended volumes. All measurements were performed at the
JRC (Geel, BE). A dilution study was also done to monitor in detail the
behaviour of the candidate material at different concentrations. Nine
commercial immunoassays were used and eight gravimetrically pre-
pared dilutions of the material were analysed. In all studies, the in-
structions and reagents of each manufacturer were used.
Statistical analysis
We compared the average results (per plate) obtained from all the
immunoassays with Analyse-it (Analyse-it software, Leeds, UK). We
calculated the Pearson’s correlation coefficient for the clinical sam-
ples for all pairs of assays. In the cases where the correlation coeffi-
cient was higher than 0.75; a linear regression was applied and the
95% prediction interval was calculated. If the results were within the
95% prediction interval of this regression the material was considered
commutable.
Homogeneity and stability of candidate RM
Fourteen randomly selected vials along the whole batch were
analysed for the homogeneity study. The number of selected vials
corresponds to approximately the cubic root of the total number of
produced vials. Each vial was gravimetrically reconstituted and
three independent samples were analysed by ELISA (Quanta Lite
anti-β2GPI IgG, INOVA Diagnostics, San Diego, CA, USA). The
measurements were performed randomly, under repeatability con-
ditions to separate a potential analytical drift from a filling
sequence trend.
The same set of vials was simultaneously used for the long-
term stability study (up to 1 year). Vials were stored at −20 °C
and −70 °C for 0, 4, 8 and 12 months (at each temperature). The
reference temperature was set to liquid nitrogen (−150 °C). Two
vials per storage time and temperature were selected using a
random stratified sampling scheme. For the short-term stability
study, 52 vials were stored at different temperatures for 1, 2 and
4 weeks. The temperatures studied were −70 °C (reference tem-
perature), −20 °C, 4 °C, 18 °C and 60 °C, two vials for each condition
and time point.
Results
Impact of processing and treatment of the
CRM
Freeze-drying does not negatively affect the candidate
reference material
A usual characteristic of freeze-dried materials is their
increased long-term stability, which is desirable as long
as their relevant properties remain unchanged. A small
batch of the candidate reference material (RM) was
freeze-dried to compare it with an RM liquid frozen
format (stored at −70 °C). Four anti-β2GPI IgG ELISA
methods were used to measure several dilutions of both
materials. Figure 1 shows that there are no significant
differences (p>0.05) between the concentration values of
the two materials, so freeze-drying does not alter the
measured RM IgG concentration.
To characterise the freeze-dried RM, we carried out a
small commutability study.
The commutability study performed included the
measurement of dilutions of the freeze-dried RM alongside
a number of clinical samples using the same anti-β2GPI IgG
immunoassays as above. Figure 2 shows comparisons of
measurement results for the RM and the clinical samples in
pairs. Depending on the methods compared, the values for
the clinical samples hold a linear (Figure 2A, C) or non-
linear (Figure 2B) relationship and the depicted prediction
interval illustrate the region where 95% of clinical samples
measurement results are expected to lie. Even though the
scatter of the values complicates the evaluation, the RM
dilutions were within the prediction interval for all six
comparisons (three of them are shown in Figure 2), which
indicates the commutability of thematerial for themethods
used.
Reconstitution of the freeze-dried material is a sensitive
process
Reconstitution variables such as water temperature,
agitation and elapsed days until the measurement were
Figure 1: Comparison of anti-β2GPI IgG concentration (in methods’
arbitrary units) of several dilutions of the freeze-dried RM versus the
liquid frozen RM as measured by four different enzyme-linked
immunosorbent assays (ELISA) methods.
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studied with regard to inter- and intra-vial homogeneity.
Temperature had little impact but strong agitation had a
negative effect, increasing the inter-vial variability of the
measurement results (Figure 3). The optimal protocol
involved reconstitution at 25 °C with three to five manual
inversions of the vial content.
Subsequently, within-vial variability was assessed on
six groups of vials that were similarly reconstituted but
measured at different days after reconstitution (0, 1, 2, 3, 4
or 7 days). Figure 4 shows that from the second day on-
wards,mean variability of within-vialmeasurement results
Figure 2: Commutability plots (1st study) of three method
comparisons in pairs (a–c). The dots show the measurement results
for clinical samples (CS) and the crosses show the dilutions of the
candidate reference material. The solid lines are the mathematical
fitting functions for the CS values and the dotted lines represent the






Figure 3: Mean within-vial coefficients of variation and IgG con-
centration values (in standard IgG units – SGU) of the six groups of
vials measured after the different temperature, time and mixing
conditions tested (standard protocol, alternative 1, 2, 3 and 4).
Reconstitution protocols:
(A) Standard conditions: add room temperature (RT) water, weigh,
let stand for 1 h at RT, invert few times during next 1 h at RT and let at
4 °C overnight. (B) Cold reconstitution: add 4 °C water, weigh, let
stand for 1 h 4 °C, invert few times during next 1 h at 4 °C, and let at
4 °C overnight. (C) Warm reconstitution: add 37 °C water, weigh, let
stand for 1 h at 37 °C, invert few times during next 1 h at RT, and let at
4 °C overnight. (D) RT reconstitution: add RT water, weigh, let stand
for 1 h at RT, invert few times during next 1 h at RT, and let at RT
overnight. (E) Shake reconstitution: add RT water, and shake for
10 min at 2.5 intensity in orbital shaker, weigh. Invert few times
during next 1 h at 4 °C and let at 4 °C overnight.
Figure 4: Mean within-vial coefficients of variation and IgG con-
centration values (in standard IgG Units – SGU) of the six groups of
vials measured 0, 1, 2, 3, 4 or 7 days after reconstitution.
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is significantly improved. It is therefore advised to leave the
material stand at 4 °C for two days before performing any
measurement. Data also show no significant evidence of
material instability over the studied timeframe.
Commutability
Assay performance
The first step in the assessment of commutability is to
ensure the performance of the assays used. Specifically, we
monitored the equivalence of results from the different
assays, the presence or absence of systemic bias and the
effect of sample specific effects. In addition to these, we
monitored whether the candidate reference material was
equivalent to the routine clinical samples. Monitoring of
these parameters (i.e. repeatability and intermediate pre-
cision) was evaluated and ensured through the experi-
mental design that allowed for sufficient number of
replicates (minimum 3). We concluded that the scatter
observed was because of sample specific effects and not
because of the assay repeatability and performance. We
calculated the coefficient of variation (CV) of averages both
within and between plates for the absorbance signal pro-
duced by the assays at the wavelength suggested by the
manufacturers and the concentrations calculated from
these absorbances. The results, whether as ODs or con-
verted into concentrations, showed a relatively low intra-
plate variation for all ELISA assays (below 15%). On
average, the variations were lower for the optical densities
(ODs) than for the converted concentration values.
There were some situations where the CVs were higher
than 15% but these were particularly seen when the con-
centration of the CSs were at the extreme ends (whether
lower or higher) of the respective calibration curves, where
small changes in signal have a big effect on the concen-
tration. Some assays use less than five calibrators, which
are not evenly distributed across the measuring range
further, which may distort the calibration curve and
introduce further variability into the assays.
The RM analytical response upon dilution is similar to
that of clinical samples
Routine anti-β2GPI IgG immunoassays require clinical
samples to be diluted in an appropriate buffer so that their
IgG concentration value lies within the analytical
measuring range. Likewise, a reference material needs to
be diluted to generate the calibration curve. It is therefore
essential that the relationship between the analytical
response (OD) and the concentration be sufficiently similar
for clinical samples and for the reference material used for
calibration. This property is frequently referred as paral-
lelism and not only has it obvious implications in the ac-
curacy of the concentration estimates but the lack of it can
also contribute to poor correlation between different
methods, as seen before in Figure 2.
To investigate this property, dilution profiles were
obtained for several clinical samples and the candidate RM
using three different methods. Dilution effects may influ-
ence the assay response (OD values) to the concentration of
the analyte (expressed as relative dilutions). Figure 5A
shows that the assay response to varying concentrations of
analyte in the CS and the candidate RM is equivalent
(Eurodiagnostica, anti-β2-Glycoprotein I IgG ELISA test). In
other words, there is parallelism between the RM and CS
dilution curves. Therefore, the RM could be diluted to
Figure 5: Dilution curves of the RM and the CS.
(A) The measured response (OD) values are plotted for each of the
dilutions of the RM and the CS and curves are fitted for each sample.
(B) The measured OD values are plotted against the anti β2-GPI IgG
concentration of dilutions of CS, expressed as relative RM
concentration. Each symbol represents dilutions of a different
clinical sample. The solid line represents the fitting function for the
dilutions of the RM and the dotted lines correspond to the 95%
prediction interval for samples presenting the same response-
concentration relationship as the RM.
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produce a calibration curve that can be used to accurately
calculate the analyte concentration in the clinical samples.
In an equivalent manner, when CS values are nor-
malised to the RM concentration, dilution curves overlap
and most values fall within the prediction interval deter-
mined by the RM dilution curve (Figure 5B). The other two
methods employed produced similar results (not shown),
so no evidence for lack of parallelism was found.
Correlation between results from different assays
The degree of correlation of results from different assays
was evaluated by a pairwise comparison of results fromall
assays. The Pearson correlation coefficient (r) was calcu-
lated and the result interpretation was based on clinical
biostatistics rules [12] according to whichwhen the r value
ranges between 0.75 and 1, the correlation can be
considered to be very good to excellent. Tables 1 and 2
shows the Pearson correlation coefficients for all assay
comparisons. They mostly varied from moderate to very
high for most assays. For 15 assay pairs the value of r was
above 0.75, indicating a good correlation. Despite the
generally good picture of the results, there were certainly
some clinical samples that were outliers in some of the
comparisons.
Commutability of candidate reference materials
The main purpose for performing the described commut-
ability studies was to select the best material for the
eventual development of a CRM i.e. a material that would
behave in the same way as an average clinical sample. The
first, small-scale commutability study served to evaluate
the impact of freeze-drying on the commutability and
protein stability of the material. In the second study, hav-
ing confirmed that the material behaved as required, more
assays and 39 clinical samples were tested alongside a
series of dilutions for the candidate RM.
The results were evaluated for all assay combinations
for which the Pearson’ correlation coefficient was above
0.75. In correlation coefficients below 0.75, the prediction
interval is very broad. Results were analysed using
Passing-Bablok and Deming regressions and results were
evaluated with respect to the 95% prediction interval.
Overall, the commutability of the m the same manner
as the material ERM-DA470k/IFCC which is certified
amongst others for total IgG, and for which the commut-
ability studies were done in a similar way [13].
Homogeneity and stability of candidate RM
The material was found sufficiently homogeneous. Within-
unit homogeneity determines the minimum size of an
aliquot that is representative for the whole unit. The
between-unit homogeneity is important for ensuring that
any vial chosen randomly for analysis is similar to any other.
The number of selected vials corresponds to approxi-
mately the cubic root of the total number of the produced
vials; they were randomly selected using a random sam-
pling scheme covering the whole batch. Statistical analysis
of the received data showed no outlying unit means or
trends in the filling sequence.
The candidate reference material was also found stable
under controlled temperature conditions at 4 °C for up to
4 weeks during shipment (analysed with Phadia EliA β2GPI
IgG assay) and −70 °C for one-year storage (analysed with
Quanta Lite® β2GPI IgG ELISA, INOVA Diagnostics)
(Figure 6A, B, respectively). The obtained data were evalu-
ated individually for each temperature and the results were
screened for outliers using the single and double Grubbs
test. We plotted regression lines for the concentrations
versus time and tested for statistical significance. The slopes
of the regression lines were not significantly different from
Table : Immunoassays used in the studies.
Manufacturer Assay Type
st commutability study
BioRad Anti-β glycoprotein I IgG test ELISA
Eurodiagnostica Anti-β-glycoprotein I IgG test ELISA
INOVA Diagnostics QUANTA Lite® β GPI IgG ELISAa ELISA
LAPL LAPL® αβGPI HRP IgG ELISA
nd commutability study
Aesku AESKULISA β-Glyco-GM ELISA
BioRad Anti-β glycoprotein I IgG test ELISA
Euroimmun Anti-β-glycoprotein I IgG test ELISA
Immco Diagnostics ImmuLisa® Enhanced BGPI ELISA ELISA
INOVA Diagnostics QUANTA Lite® β GPI IgG ELISA ELISA
Orgentec Diagnostika Anti-beta--glycoprotein I IgG/IgM ELISA




Aesku AESKULISA β-Glyco-GM ELISA
BioRad Anti-β glycoprotein I IgG test ELISA
BioRad BioPlex®  APLS IgG MFI
Euroimmun anti-β-Glycoprotein I IgG test ELISA
Immco Diagnostics ImmuLisa® Enhanced BGPI ELISA ELISA
INOVA Diagnostics QUANTA Lite® β GPI IgG ELISAa ELISA
INOVA Diagnostics QUANTA Flash(R) (B)GP Domain  CIA
Reaads IgG anti-beta  glycoprotein
I semi-quantitative test kit
ELISA
aQUANTA Lite® assay was used twice in two different laboratories.
ELISA, enzyme linked immunosorbent assay; MFI, multiplex flow
immunoassay; CIA, Chemiluminescent Immunoassays.
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zero (at a 99%confidence level) at−20 °C, 4 °C and 18 °C. The
material was found stable at all temperatures.
Concerning the materials’ long-term stability, vials
were stored at −20 °C and −70 °C for 0, 4, 8 and 12 months
(at each temperature). The reference temperaturewas set at
liquid nitrogen (−150 °C). Analysis of two vials per tem-
perature showed that the material could be safely stored at
either of the tested temperatures. The candidate reference
material for anti-β2GPI IgG has been also tested for its
stability five years after its production and was found
similarly stable (data not shown).
Discussion
Development of the CRM
The impact of the lack of standardisation on laboratory
results can unarguably be severe, as it has already been
shown in several EQAS reports [10, 14]. To be of any value, a
laboratory result needs to be accurate and conclusive. This
is the only way to ensure that the requesting clinician will
be assisted in delivering correct diagnosis, prognosis and
monitoring of a disease. Undoubtedly, most of the assays
available in the market are able to deliver independently
quality results. Nevertheless, these results may vary be-
tween the assays causing confusion. Hutu et al. has shown
in a commutability study for one of the biomarkers for
small vessel-associated vasculitis, that only 10 out the 30
clinical samples tested had the same classification
amongst the assays used [15]. This variability decreased
when the developed CRM was used for recalculation of the
results [16].
The results of these studies as for many others in
the field of clinical chemistry or immunology or hae-
matology, confirm the variability in anti-β2GPI IgG
testing, even though all participating assays and labo-
ratories perform generally well in terms of precision.
From the studies we have finalised, we have identified
a material that is commutable when freeze-dried. We
have performed studies confirming its short-term (dur-
ing transport) and long-term (during storage) stability
under various conditions of temperature and time. For
the assignment of a concentration value to this mate-
rial, we are in close collaboration with the National
Institute for Biological Standards and Control (NIBSC).
Our findings are to be submitted to the WHO in the
near future with a request of assignment of units in IU/
Table : Pearson correlation coefficients for all assay comparisons.
Figure 6: Stability data (results of individual replicates) of
ERM-DA477/IFCC; measured values by ELISA (arbitrary units, U/mL),
when stored for several weeks at 4 °C (A) and severalmonths at−70 °C
(B). Results at time point 0 correspond to units that were stored at the
reference temperature of liquid nitrogen.
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vial to the material. Assuming a success of our efforts,
such a material could be used to reduce inter- and
intra-assay variability, eventually improving [5] lot-to-
lot variation [15, 17].
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